Article Text

Download PDFPDF

miR-138 exerts anti-glioma efficacy by targeting immune checkpoints
  1. Jun Wei1,
  2. Edjah Nduom1,
  3. Ling-Yuan Kong1,
  4. Fei Wang1,
  5. Shuo Xu1,2,
  6. Konrad Gabrusiewicz1,
  7. Ali Alum1,
  8. Greg Fuller1,
  9. George Calin1 and
  10. Amy B Heimberger1
  1. Aff1 grid.240145.60000000122914776University of Texas MD Andrson Cancer Center Houston TX USA
  2. Aff2 grid.452402.5Qilu Hospital of Shandong University Jinan China

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts

The immune checkpoints, CTLA-4 and PD-1, are negative regulators of T cell activation and are inducers of FoxP3+ Tregs. Monoclonal antibody therapy to each has demonstrated tumor regression in clinical trials and potent therapeutic synergy has been observed when used in combination. MicroRNAs (miRs) have been shown to modulate gene transcripts involved in tumorigenesis and can target tumor-mediated immune suppression. On the basis of differential miRNA gene expression libraries from glioblastoma patients, miR-138 was identified as a top down regulated candidate. On glioma tumor microarrays, miR-138 expression is heterogeneous among the various grades and pathologies. Target binding algorithms predicted that miR-138 could bind CTLA-4 and PD-1. Transfection of human CD4+ T cells with miR-138 suppressed CTLA-4-, PD-1-, and FoxP3- expression in vitro. Treatment of established subcutaneous GL261 murine glioma cells in immune competent C57BL/6 mice with miR-138 or scramble control administered intravenously demonstrated that gliomas started to shrink as soon as miR-138 was administered. Moreover, the gliomas continued to regress even after miR-138 treatment was discontinued. In contrast, tumors kept growing aggressively in scramble miRNA-treated and untreated tumor-bearing mice groups. Furthermore, in C57BL/6 mice with established intracerebral GL261 treated with i.v. administered miR-138, median survival was 33.5 days relative to mice treated with scramble control with a median survival of 23.5 days (P=0.011). Intravenous treatment of mice with established intracerebral gliomas with miR-138 relative to the scramble control reduced the relative incidence of Tregs by 51% (P=0.03) within the glioma microenvironment. Formulation equivalency studies in vivo indicate that DOTAP causes rapid translocation of miRNAs into the peripheral blood compartment indicating that miR-138 may have rapid translational potential as a novel immunotherapeutic agent for neoplasms.